Divozilimab

DB18878InvestigationalProtein Based Therapies

Divozilimab is under investigation in clinical trial NCT05730699 (Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human cd20 antigen) (human-mus musculus monoclonal bcd-132 .gamma.1-chain), disulfide with human-mus musculus monoclonal bcd-132 .kappa.-chain, dimer

Resolves to

Compound

UNII13ZEQ1M5MLCAS2254061-60-2

Clinical / RWD

ATCL04AG15

Targets

P11836MS4A1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 8 drug categories

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Divozilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account